Aeterna Zentaris to Announce Fourth Quarter and Year End 2017 Financial and Operating Results on March 28th, 2018
March 21 2018 - 3:05PM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS)
will announce its fourth quarter and year ended December 31, 2017
financial and operating results after market close on Tuesday,
March 27th, 2018. The Company will host a conference call to
discuss these results on Wednesday, March 28th, 2018 at 8:30 a.m.
Eastern Time.
Participants may access the live conference call
by telephone using the following numbers: (Toll-Free):
877-407-8029, (Toll): 201-689-8029, Confirmation #13677806. A
replay will also be available on the Company’s website for a period
of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company focused on developing and
commercializing, principally through out-licensing arrangements,
Macrilen™ (macimorelin), an orally available ghrelin agonist, to be
used in the diagnosis of patients with adult growth hormone
deficiency (AGHD). On January 17, 2018 Aeterna Zentaris announced
that that it had, through a wholly-owned subsidiary, entered into a
license and assignment agreement with a wholly-owned subsidiary of
Strongbridge Biopharma plc to carry out development, manufacturing,
registration and commercialization of Macrilen™ (macimorelin) in
the United States and Canada. On December 20, 2017 the Company
announced that the U.S. Food and Drug Administration (FDA) granted
marketing approval for Macrilen™ (macimorelin). On November 27,
2017 Aeterna Zentaris announced that the Marketing Authorization
Application (MAA) for the use of Macrilen™ (macimorelin) for the
evaluation of AGHD was accepted by the European Medicines Agency
(EMA) for regulatory review. For more information,
visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking
statements made pursuant to the safe-harbor provisions of the U.S.
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws, which reflect our current expectations regarding
future events. Forward-looking statements may include, but are not
limited to statements preceded by, followed by, or that include the
words “expects,” “believes,” “intends,” “would,” “could,” “may,”
“anticipates,” and similar terms that relate to future events,
performance, or our results. Forward-looking statements involve
known risks and uncertainties, many of which are discussed under
the caption “Key Information - Risk Factors” in our most recent
Annual Report on Form 20-F filed with the relevant Canadian
securities regulatory authorities in lieu of an annual information
form and with the U.S. Securities and Exchange Commission (“SEC”)
and under the caption “Risk Factors and Uncertainties” in our
management’s discussion and analysis for the third quarter of 2017.
Such statements include, but are not limited to, statements about
the merit or outcome of the class action lawsuit, the Company’s
intention and ability to defend such legal actions, and the
availability of insurance to cover costs and expenses relating to
the defense of the lawsuit. Known and unknown risks and
uncertainties could cause our actual results to differ materially
from those in forward-looking statements. Such risks and
uncertainties include, effect of the class action lawsuit and other
litigation, on our cash flow, results of operations and financial
position. Investors should consult the Company’s quarterly and
annual filings with the applicable Canadian securities regulators
and the SEC for additional information on risks and uncertainties.
Given these uncertainties and risk factors, readers are cautioned
not to place undue reliance on these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments,
unless required to do so by a governmental authority or applicable
law.
Contacts:Aeterna Zentaris Inc.Michael V.
WardChief Executive OfficerIR@aezsinc.com843-900-3201
Reilly ConnectSusan
ReillyPresidentsusan.reilly@reillyconnect.com312-600-6783
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024